suma/obesity

RELATED APPLICATIONS This is a .sctn.371 of International Application No. PCT/JP2009/063632, with an international filing date of Jul. 31, 2009 (WO 2010/013798 A1, published Feb. 4, 2010), which is based on Japanese Patent Application No. 2008-198047, filed Jul. 31, 2008, the subject matter of which

This invention relates to pharmaceutical compositions which contain as the active ingredient the compound 1-(4-hydroxy-3-dimethylamino-sulfonamidophenyl)-1-hydroxy-2-(1-phenoxy-iso propylamino)ethane (Me 693), and to a method of treating both generalized and also localized obesity in warm-blooded

This invention relates to anti-obesity agents and their use in preventing or treating obesity in mammals, particularly humans. Hitherto the usual method employed to treat obesity in man has been to reduce the intake of food either by a low calorie diet or by the use of appetite suppressant

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to a novel azetidine derivative having excellent pharmacological action. 2. Description of the Prior Art German Patent Application Laid-Open No. 2653407 (DE-OS2653407) refers to 2-(.alpha.-hydroxybenzyl)azetidine and its

FIELD OF THE INVENTION The present invention is directed to compositions and methods that are useful in the treatment and prevention of obesity. BACKGROUND OF THE INVENTION Obesity, an extremely common and detrimental metabolic disease, poses serious threats to the public health both in the US and

FIELD OF THE INVENTION The present invention is directed to compositions and methods that are useful in the treatment and prevention of obesity. BACKGROUND OF THE INVENTION Obesity, an extremely common and detrimental metabolic disease, poses serious threats to the public health both in the US and

BACKGROUND OF THE INVENTION The present invention relates to novel N-sulfamoyl-piperidineamides and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and related

FIELD OF THE INVENTION The invention relates to compositions for the treatment of obesity and related diseases, comprising the administration of a therapeutically effective amount of Flibanserin. The invention relates further to new pharmaceutical compositions for the treatment of obesity and

FIELD OF THE INVENTION The invention relates to compositions for the treatment of obesity and related diseases, comprising the administration of a therapeutically effective amount of Flibanserin. The invention relates further to new pharmaceutical compositions for the treatment of obesity and

Incorporated by reference in its entirety is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 185 KB ACII (Text) file named 214815SubSeqListing.txt created on Oct. 4, 2013. BACKGROUND Pre-proglucagon is a 158 amino acid

The invention concerns novel therapeutic agents having thermogenic properties for use in the treatment of obesity and/or related conditions such as diabetes mellitus especially of maturity onset, in warm-blooded animals such as man. More particularly, the invention provides a new method of treatment

BACKGROUND OF THE INVENTION Tertiary 2-phenoxy-2-phenylethylamines constitute the subject matter of U.S. Pat. No. 3,106,564. The compounds are said to be useful pharmacological agents exhibiting activity on the central nervous system including useful application as analeptic agents without

BACKGROUND Overweight and obesity represent the prevalent nutritional problem in the developed countries. According to World Health Organization estimates, more than 300 million adults are obese worldwide. In general, energy intake exceeding energy expenditures for a longer time results in abnormal

FIELD OF THE INVENTION The present invention provides a method for treating obesity or causing weight loss in a mammal employing an SGLT2 inhibitor alone or in combination with another anti-obesity agent, and to a pharmaceutical composition for use in such method. BACKGROUND OF THE

FIELD OF THE INVENTION The present invention provides a method for treating obesity or causing weight loss in a mammal employing an SGLT2 inhibitor alone or in combination with another anti-obesity agent, and to a pharmaceutical composition for use in such method. BACKGROUND OF THE